mirtazapine has been researched along with Lung Diseases, Interstitial in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial." | 6.94 | Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). ( Bajwah, S; Best, E; Brown, S; Crosby, V; Currow, D; Hart, SP; Higginson, IJ; Johnson, MJ; Lovell, N; Poad, H; Wilcock, A; Yi, D, 2020) |
| "Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial." | 2.94 | Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). ( Bajwah, S; Best, E; Brown, S; Crosby, V; Currow, D; Hart, SP; Higginson, IJ; Johnson, MJ; Lovell, N; Poad, H; Wilcock, A; Yi, D, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higginson, IJ | 1 |
| Wilcock, A | 1 |
| Johnson, MJ | 1 |
| Bajwah, S | 1 |
| Lovell, N | 1 |
| Yi, D | 1 |
| Hart, SP | 1 |
| Crosby, V | 1 |
| Poad, H | 1 |
| Currow, D | 1 |
| Best, E | 1 |
| Brown, S | 1 |
1 trial available for mirtazapine and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2020 |